enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Hold” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned a consensus rating of “Hold” from the fourteen brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $11.0455.

Several analysts have recently commented on the stock. Piper Sandler downgraded shares of enGene from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $7.00 to $4.00 in a report on Friday, May 8th. Wells Fargo & Company restated an “equal weight” rating and set a $2.00 price target (down from $25.00) on shares of enGene in a report on Friday, May 8th. Citigroup downgraded shares of enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday, May 8th. UBS Group reduced their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings lowered shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 15th.

Hedge Funds Weigh In On enGene

Several institutional investors have recently modified their holdings of ENGN. Cresset Asset Management LLC purchased a new stake in shares of enGene during the second quarter valued at approximately $36,000. Paloma Partners Management Co purchased a new position in enGene in the second quarter worth $38,000. Raymond James Financial Inc. boosted its position in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares during the last quarter. PFS Partners LLC grew its stake in enGene by 22.2% in the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock valued at $99,000 after purchasing an additional 2,000 shares during the period. Finally, Jump Financial LLC bought a new position in enGene in the 4th quarter valued at $121,000. 64.16% of the stock is owned by institutional investors.

enGene Stock Performance

Shares of enGene stock opened at $1.79 on Wednesday. The company has a market capitalization of $119.90 million, a P/E ratio of -0.82 and a beta of -0.28. The stock has a fifty day simple moving average of $1.78 and a 200 day simple moving average of $5.58. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. During the same period in the prior year, the firm earned $0.51 EPS. On average, sell-side analysts anticipate that enGene will post -1.84 earnings per share for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.